Top Markets
#1 MowCat MowCat +779.10%
#2 龙虾 (Lobster) 龙虾 (Lobster) +84.18%
#3 Magma Finance Magma Finance +38.31%
#4 Akedo Akedo +38.00%
#5 MarsCoin MarsCoin +31.11%
#6 SIXSEVEN SIXSEVEN +30.85%
#7 Cortex Cortex +25.84%
#8 DeXe DeXe +19.90%
#9 Pons Pons +15.98%
#10 OpenEden OpenEden +14.56%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
Zhejiang Jolly Pharmaceutical Co.,LTD Zhejiang Jolly Pharmaceutical Co.,LTD

Zhejiang Jolly Pharmaceutical Co.,LTD

300181
Rank in Stocks #8004
Zhejiang Jolly Pharmaceutical Co., Ltd. is a Chinese enterprise dedicated to... Zhejiang Jolly Pharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the research, manufacturing, and global distribution of traditional Chinese medicinal products. The company's diverse portfolio includes the Wuling capsule, prescribed for conditions such as insomnia, amnesia, heart palpitations, general fatigue, weakness in the lower back and legs, and tinnitus. This capsule also addresses energy deficiency and a weak pulse often linked to an imbalance of the heart and kidneys, or neurasthenia. Additionally, they produce the Lingze tablet, which targets frequent or painful urination, weak or continuous urine flow, and lower back and knee soreness, especially when these symptoms are associated with benign prostatic hyperplasia, kidney insufficiency, or blood stasis. Another offering, the Bailing tablet, serves as an adjunctive treatment for coughs, asthma, back pain, and chronic bronchitis stemming from lung and kidney deficiencies. The firm also markets Linglianhua particles, used to manage symptoms including excessive sweating, sleep disturbances, irritability, heart flutters, vivid dreams, dizziness with tinnitus, lower back and leg weakness, dry stools, an unusual tongue appearance, and a feeble pulse, often seen in perimenopausal syndrome or heart and kidney disharmony. Beyond these traditional Chinese medicine formulations, Zhejiang Jolly Pharmaceutical provides a range of injectable pharmaceuticals, such as azithromycin, clindamycin phosphate, doxapram, pefloxacin mesylate, adenosine cyclophosphate, and sodium nitroprusside. The company further supplies raw medicinal ingredients, including cordyceps cephalosporium, fermented cordyceps, and Wuling powders. Expanding its reach into healthcare services, Zhejiang Jolly Pharmaceutical Co., Ltd. invests in and participates with Deqing No.3 People's Hospital. Established in 2000 and based in Huzhou, China, the entity now known as Zhejiang Jolly Pharmaceutical Co., Ltd. adopted this name in 1998, evolving from its earlier designation, Zhejiang Jolly Pharmaceutical Health Products Co., LTD.
Share Price
$2.00
Market Cap
$1.39B
Change (1 day)
-2.67%
Change (1 year)
-25.13%
Country
CN
Trade Zhejiang Jolly Pharmaceutical Co.,LTD (300181)

Category

Healthcare
P/E ratio for Zhejiang Jolly Pharmaceutical Co.,LTD (300181)
P/E ratio as of 2026 TTM: 0
According to Zhejiang Jolly Pharmaceutical Co.,LTD latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Zhejiang Jolly Pharmaceutical Co.,LTD from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.